Cellectis S.A. (CLLS): Price and Financial Metrics
CLLS Price/Volume Stats
Current price | $2.70 | 52-week high | $3.77 |
Prev. close | $2.67 | 52-week low | $0.96 |
Day low | $2.65 | Volume | 24,051 |
Day high | $2.75 | Avg. volume | 42,252 |
50-day MA | $2.73 | Dividend yield | N/A |
200-day MA | $2.33 | Market Cap | 150.08M |
CLLS Stock Price Chart Interactive Chart >
Cellectis S.A. (CLLS) Company Bio
Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.
Latest CLLS News From Around the Web
Below are the latest news stories about CELLECTIS SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommenda |
Monthly information on share capital and company voting rights(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights11/30/202371,751,20177,686,109 For further information on Cellectis, please contact: Media contact: Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, [email protected] Investor Relations contacts: Arthur Stril, Chief Business Off |
Cellectis’ Shareholders Meeting to be Held on December 22, 2023NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the a |
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaExecution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders’ meeting of Cellectis to be held on or around December 22, 2023 to approve such investment. NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investm |
Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call TranscriptCellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings Calls. [Operator Instructions]. I’d now like to introduce the first speaker Arthur Stril, Chief Business Officer. You may begin. Arthur Stril: Good morning, and welcome, everyone, to Cellectis third quarter 2023 […] |
CLLS Price Returns
1-mo | -0.74% |
3-mo | -12.34% |
6-mo | 70.89% |
1-year | 41.36% |
3-year | -85.86% |
5-year | -85.28% |
YTD | -12.34% |
2023 | 46.67% |
2022 | -74.14% |
2021 | -69.99% |
2020 | 58.06% |
2019 | 2.82% |
Continue Researching CLLS
Want to see what other sources are saying about Cellectis SA's financials and stock price? Try the links below:Cellectis SA (CLLS) Stock Price | Nasdaq
Cellectis SA (CLLS) Stock Quote, History and News - Yahoo Finance
Cellectis SA (CLLS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...